Key facts
- Newleos Therapeutics’s last known valuation is $150.0M (Feb 2025).
- It has raised $93.5M across 1 recorded rounds; the latest was Later Stage VC ($93.4M) in Feb 2025.
- Notable investors include Novo Holdings, Goldman Sachs Asset Management, Dolby Family Ventures, Arkin Capital, DCVC Bio — 6 tracked in total.
- Newleos Therapeutics has filed 1 Form D with the SEC, most recently Feb 2025 ($93.4M sold to 11 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Newleos Therapeutics
Funding rounds
1 roundsAbout Newleos Therapeutics
Developer of a clinical-stage biotechnology platform designed to advance new treatments for mental health conditions through innovative neuroscience research. The company's platform offers orally administered small-molecule drug candidates targeting novel neuropsychiatric pathways, enabling patients and healthcare providers to address anxiety, substance use disorders, and cognitive impairment with improved tolerability and outcomes.
- Sector
- Healthcare
- HQ
- Boston, MA, United States
- Founded
- 2009
- Employees
- 23
- Website
- newleos.com/
- Ownership
- Privately Held (backing)
Newleos Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Newleos Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Newleos Therapeutics in its N-PORT filings yet. We sweep new filings monthly.